Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company’s product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. operates as a subsidiary of Innoviva, Inc.
Metrics to compare | ARMP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipARMPPeersSector | |
---|---|---|---|---|
P/E Ratio | −203.1x | −4.7x | −0.5x | |
PEG Ratio | −4.00 | 0.00 | 0.00 | |
Price/Book | −1.6x | 6.1x | 2.6x | |
Price / LTM Sales | 18.4x | 9.3x | 3.2x | |
Upside (Analyst Target) | 276.6% | 112.0% | 41.4% | |
Fair Value Upside | Unlock | 15.7% | 6.0% | Unlock |